Form 4: Paula A. Price Reports Acquisition of Deferred Share Units in Bristol-Myers Squibb Co.

Director Paula A. Price reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Summary

• On February 1, 2025, Paula A. Price, a director of Bristol-Myers Squibb Co. (BMY), acquired 3,562.341 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Price ceases to be a director or at a previously specified future date.
• The price of the derivative security is $58.95.
• Following the transaction, Price beneficially owns 20,434.092 derivative securities, which includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings of company directors.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in the director's holdings, but it doesn't indicate a significant shift in company strategy or performance.

Key Dates

Keywords

Form 4, Bristol-Myers Squibb, Deferred Share Units, Beneficial Ownership, Director, Paula A. Price, BMY